Literature DB >> 7453820

Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages.

J S Peiris, S Gordon, J C Unkeless, J S Porterfield.   

Abstract

Flaviviruses, when complexed with antibody at subneutralizing concentrations, show enhanced replication in human and simian peripheral blood leukocytes (ref. 1, and J.S.M.P. and J.S.P., unpublished observations) and in P388 D1 and other macrophage cell lines. A comparable phenomenon has been demonstrated with alphaviruses and Bunyaviruses in P388 D1 cells, (J.S.M.P. and J.S.P., unpublished observations) but cells lacking macrophage characteristics fail to show antibody-dependent enhancement (ADE) of viral replication. It has been suggested that the macrophage Fc receptor (FcR) provides an efficient route of entry of virus through the attachment of non-neutralized virus-antibody complexes and that for those viruses that escape destruction by the phagocyte, antibody results in a paradoxical increase in virus replication. West Nile virus (WNV) replication in the P388 D1 macrophage cell line provides a reproducible model system for studying ADE of viral replication. Mouse macrophages have two FcRs-FcRI, which is trypsin-sensitive and binds IgG2a, and FcRII, which is trypsin-resistant and binds IgG2b and IgG1 complexes. The FcR has been purified using rat anti-mouse FcR monoclonal antibody which blocks FcRII. We show here that anti-FcRIgG and its Fab fragment block ADE of virus replication by anti-WNV monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7453820     DOI: 10.1038/289189a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  47 in total

1.  Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys.

Authors:  N M Ferguson; C A Donnelly; R M Anderson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-04-29       Impact factor: 6.237

2.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

3.  The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens.

Authors:  N Ferguson; R Anderson; S Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

4.  Characterization of protein involvement in rabies virus binding to BHK-21 cells.

Authors:  J H Broughan; W H Wunner
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes.

Authors:  R Anderson; S Wang; C Osiowy; A C Issekutz
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Increase of retroviral infection in vitro by the binding of antiretroviral antibodies.

Authors:  P Legrain; B Goud; G Buttin
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

7.  Propagation of an attenuated virus by design: engineering a novel receptor for a noninfectious foot-and-mouth disease virus.

Authors:  E Rieder; A Berinstein; B Baxt; A Kang; P W Mason
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

8.  Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.

Authors:  Kristina von Kietzell; Tanja Pozzuto; Regine Heilbronn; Tobias Grössl; Henry Fechner; Stefan Weger
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Dengue virus selectively induces human mast cell chemokine production.

Authors:  Christine A King; Robert Anderson; Jean S Marshall
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.